JP2016534134A5 - - Google Patents

Download PDF

Info

Publication number
JP2016534134A5
JP2016534134A5 JP2016540436A JP2016540436A JP2016534134A5 JP 2016534134 A5 JP2016534134 A5 JP 2016534134A5 JP 2016540436 A JP2016540436 A JP 2016540436A JP 2016540436 A JP2016540436 A JP 2016540436A JP 2016534134 A5 JP2016534134 A5 JP 2016534134A5
Authority
JP
Japan
Prior art keywords
hydroxy
alkyl
cyano
compound
item
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016540436A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016534134A (ja
JP6486940B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/054375 external-priority patent/WO2015035223A1/en
Publication of JP2016534134A publication Critical patent/JP2016534134A/ja
Publication of JP2016534134A5 publication Critical patent/JP2016534134A5/ja
Application granted granted Critical
Publication of JP6486940B2 publication Critical patent/JP6486940B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016540436A 2013-09-09 2014-09-05 アリールエーテルおよびその使用 Active JP6486940B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361875674P 2013-09-09 2013-09-09
US61/875,674 2013-09-09
US201461978421P 2014-04-11 2014-04-11
US61/978,421 2014-04-11
PCT/US2014/054375 WO2015035223A1 (en) 2013-09-09 2014-09-05 Aryl ethers and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019018100A Division JP6746733B2 (ja) 2013-09-09 2019-02-04 アリールエーテルおよびその使用

Publications (3)

Publication Number Publication Date
JP2016534134A JP2016534134A (ja) 2016-11-04
JP2016534134A5 true JP2016534134A5 (https=) 2017-10-12
JP6486940B2 JP6486940B2 (ja) 2019-03-20

Family

ID=52628976

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2016540436A Active JP6486940B2 (ja) 2013-09-09 2014-09-05 アリールエーテルおよびその使用
JP2019018100A Active JP6746733B2 (ja) 2013-09-09 2019-02-04 アリールエーテルおよびその使用
JP2019052947A Active JP6918039B2 (ja) 2013-09-09 2019-03-20 アリールエーテルおよびその使用
JP2019052946A Pending JP2019089855A (ja) 2013-09-09 2019-03-20 アリールエーテルおよびその使用

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2019018100A Active JP6746733B2 (ja) 2013-09-09 2019-02-04 アリールエーテルおよびその使用
JP2019052947A Active JP6918039B2 (ja) 2013-09-09 2019-03-20 アリールエーテルおよびその使用
JP2019052946A Pending JP2019089855A (ja) 2013-09-09 2019-03-20 アリールエーテルおよびその使用

Country Status (33)

Country Link
US (7) US9908845B2 (https=)
EP (4) EP3043784B9 (https=)
JP (4) JP6486940B2 (https=)
KR (1) KR102153772B1 (https=)
CN (2) CN110372550B (https=)
AU (1) AU2014318025B2 (https=)
BR (1) BR112016005262B1 (https=)
CA (1) CA2919397C (https=)
CU (1) CU24385B1 (https=)
CY (3) CY1122144T1 (https=)
DK (1) DK3043784T3 (https=)
EA (1) EA032124B1 (https=)
ES (3) ES2739433T3 (https=)
FI (1) FIC20253001I1 (https=)
FR (1) FR25C1018I2 (https=)
HR (2) HRP20201701T8 (https=)
HU (3) HUE045462T2 (https=)
IL (1) IL243888B (https=)
LT (3) LT3417851T (https=)
MX (1) MX2016002974A (https=)
MY (1) MY199426A (https=)
NL (1) NL301327I2 (https=)
NO (1) NO2025022I1 (https=)
PE (1) PE20160434A1 (https=)
PL (2) PL3417851T3 (https=)
PT (2) PT3043784T (https=)
RS (2) RS58960B1 (https=)
SG (1) SG11201601616SA (https=)
SI (2) SI3043784T1 (https=)
SM (1) SMT201900479T1 (https=)
TW (2) TW201936572A (https=)
UY (1) UY35731A (https=)
WO (1) WO2015035223A1 (https=)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2687481T3 (es) 2013-03-15 2018-10-25 Chromocell Corporation Moduladores del canal de sodio para el tratamiento del dolor
PL3417851T3 (pl) 2013-09-09 2020-12-14 Peloton Therapeutics, Inc. Etery arylowe i ich zastosowanie
AU2014318979B2 (en) 2013-09-10 2019-03-28 Chromocell Corporation Sodium channel modulators for the treatment of pain and diabetes
US9884843B2 (en) 2013-12-16 2018-02-06 Peloton Therapeutics, Inc. Cyclic sulfone and sulfoximine analogs and uses thereof
WO2016057242A1 (en) * 2014-10-10 2016-04-14 The Board Of Regents Of The University Of Texas System HIF-2α INHIBITORS FOR TREATING IRON OVERLOAD DISORDERS
US10512626B2 (en) * 2015-03-11 2019-12-24 Peloton Therapeautics, Inc. Compositions for use in treating glioblastoma
WO2016144826A1 (en) * 2015-03-11 2016-09-15 Peloton Therapeutics, Inc. Substituted pyridines and uses thereof
WO2016145236A1 (en) * 2015-03-11 2016-09-15 Peloton Therapeutics, Inc. Hif-2-alpha inhibitor polymorphs
WO2016144825A1 (en) 2015-03-11 2016-09-15 Peloton Therapeutics, Inc. Aromatic compounds and uses thereof
US10278942B2 (en) 2015-03-11 2019-05-07 Peloton Therapeutics, Inc. Compositions for use in treating pulmonary arterial hypertension
WO2016168510A1 (en) 2015-04-17 2016-10-20 Peloton Therapeutics, Inc. Combination therapy of a hif-2-alpha inhibitor and an immunotherapeutic agent and uses thereof
US9796697B2 (en) 2015-06-12 2017-10-24 Peloton Therapeutics, Inc. Tricyclic inhibitors of HIF-2-alpha and uses thereof
CN105566406A (zh) * 2015-12-30 2016-05-11 江西胜富化工有限公司 一种氟代脱氧呋喃核糖的制备方法
WO2018031680A1 (en) * 2016-08-10 2018-02-15 Fronthera U.S. Pharmaceuticals Llc Novel compounds, uses and methods for their preparation
CN110167939B (zh) * 2017-01-11 2021-12-31 江苏豪森药业集团有限公司 吡咯并[2,3-c]吡啶类衍生物、其制备方法及其在医药上的应用
WO2018160772A1 (en) 2017-02-28 2018-09-07 The United State Of America, As Represented By The Secretary, Department Of Health & Human Services Method of treating obesity, insulin resistance, non-alcoholic fatty liver disease including non-alcoholic steatohepatitis
TWI642658B (zh) 2017-11-01 2018-12-01 國立臺灣師範大學 茚並異喹啉衍生物的製備方法
EP3713644B1 (en) 2017-11-20 2024-08-07 University of Georgia Research Foundation, Inc. Compositions and methods for modulating hif-2a to improve muscle generation and repair
EP3774709A4 (en) * 2018-03-28 2021-12-22 Peloton Therapeutics, Inc. METHOD FOR REDUCING INFLAMMATION OF THE DIGESTIVE SYSTEM USING INHIBITORS OF HIF-2-ALPHA
EP3793989B1 (en) 2018-05-18 2024-08-21 Merck Patent GmbH Thiophene derivatives
US12171741B2 (en) 2018-09-11 2024-12-24 Nikang Therapeutics, Inc. 2,3-dihydrobenzo[b]thiophene derivatives as hypoxia inducible factor-2(alpha) inhibitors
WO2020081695A1 (en) 2018-10-17 2020-04-23 Nikang Therapeutics, Inc. Indane derivatives as hypoxia inducible factor-2(alpha) inhibitors
CN112955130A (zh) * 2018-10-30 2021-06-11 佩洛通治疗公司 包含取代茚满的固体分散体和药物组合物及其制备和使用方法
CN109776607B (zh) * 2019-02-21 2021-06-04 青岛海洋生物医药研究院 芳基磷氧类和芳基磷硫类化合物及其制备方法和应用
IL287258B2 (en) * 2019-04-18 2026-01-01 Nikang Therapeutics Inc Inhibitors as tetrahydro-1h-cyclopenta[cd] indene derivatives as hypoxia inducible factor -2alpha
CN118561817A (zh) 2019-07-23 2024-08-30 拜耳公司 作为农药的新的杂芳基-三唑化合物
US20220402916A1 (en) 2019-09-18 2022-12-22 Merck Sharp & Dohme Corp. Small molecule inhibitors of kras g12c mutant
US11576889B2 (en) 2019-09-23 2023-02-14 The Board Of Regents Of The University Of Texas System Methods of identifying and treating patients with HIF-2 inhibitor resistance
UA129778C2 (uk) 2019-10-28 2025-07-30 Мерк Шарп Енд Доум Елелсі Низькомолекулярні інгібітори g12c-мутантного kras
US20230023023A1 (en) 2019-10-31 2023-01-26 Taiho Pharmaceutical Co., Ltd. 4-aminobut-2-enamide derivatives and salts thereof
CN112812136B (zh) * 2019-11-15 2022-04-12 武汉光谷亚太医药研究院有限公司 新型2,3-二氢化茚衍生化合物、制备方法和应用
TW202136248A (zh) 2019-11-25 2021-10-01 德商拜耳廠股份有限公司 作為殺蟲劑之新穎雜芳基-三唑化合物
CA3162574A1 (en) 2019-11-26 2021-06-03 Merck Patent Gmbh Condensed thiophene derivatives as hypoxia inducible factor (hif) inhibitors
WO2021106231A1 (en) 2019-11-29 2021-06-03 Taiho Pharmaceutical Co., Ltd. A compound having inhibitory activity against kras g12d mutation
JP2023504623A (ja) * 2019-12-04 2023-02-06 アーカス バイオサイエンシーズ,インコーポレーテッド Hif-2アルファの阻害剤
CN111214484B (zh) * 2020-01-21 2021-04-06 北京工商大学 一种共轭聚合物和聚集诱导发光小分子共掺的纳米粒子及其制备方法和应用
CN113387848B (zh) * 2020-03-12 2022-11-22 上海交通大学 一种制备磺酰胺类化合物的合成工艺
CN119118872A (zh) 2020-03-19 2024-12-13 艾库斯生物科学有限公司 作为HIF-2α抑制剂的四氢化萘和四氢喹啉化合物
US11420936B2 (en) 2020-04-16 2022-08-23 Nikang Therapeutics, Inc. Hypoxia inducible factor-2(alpha) inhibitors and their use in the treatment of diseases
WO2021215545A1 (en) 2020-04-24 2021-10-28 Taiho Pharmaceutical Co., Ltd. Anticancer combination therapy with n-(1-acryloyl-azetidin-3-yl)-2-((1h-indazol-3-yl)amino)methyl)-1h-imidazole-5-carboxamide inhibitor of kras-g12c
WO2021215544A1 (en) 2020-04-24 2021-10-28 Taiho Pharmaceutical Co., Ltd. Kras g12d protein inhibitors
TWI891782B (zh) 2020-05-06 2025-08-01 德商拜耳廠股份有限公司 作為殺蟲劑之新穎雜芳基三唑化合物
CA3186769A1 (en) * 2020-06-11 2021-12-16 Betta Pharmaceuticals Co., Ltd Bicyclic compounds and use thereof
CN115667190B (zh) * 2020-06-17 2024-10-11 贝达药业股份有限公司 双环类化合物及其应用
WO2021261601A1 (ja) 2020-06-26 2021-12-30 ラクオリア創薬株式会社 レチノイドとがん治療薬との併用療法が有効ながん患者の選択方法およびレチノイドとがん治療薬との併用医薬
EP4183395A4 (en) 2020-07-15 2024-07-24 Taiho Pharmaceutical Co., Ltd. PYRIMIDINE COMPOUND-CONTAINING COMBINATION FOR USE IN TUMOR TREATMENT
WO2022063115A1 (zh) * 2020-09-24 2022-03-31 贝达药业股份有限公司 双环化合物及其应用
WO2022082329A1 (en) * 2020-10-19 2022-04-28 Nikang Therapeutics, Inc. Processes of preparing 3-fluoro-5- ( ( (1s, 2ar) -1, 3, 3, 4, 4-pentafluoro-2a-hydroxy-2, 2a, 3, 4-tetrahydro-1h-cyclopenta [cd] inden-7-yl) oxy) -benzonitrile
WO2022082337A1 (en) 2020-10-19 2022-04-28 Nikang Therapeutics, Inc. Process of preparing 3-fluoro-5 ( ( (1r, 2ar) -3, 3, 4, 4-tetrafluoro-1, 2a-dihydroxy-2, 2a, 3, 4-tetrahydro-1h-cyclopenta [cd] inden-7-yl) oxy) benzonitrile
WO2022086882A1 (en) 2020-10-21 2022-04-28 Nikang Therapeutics, Inc. Diagnostic and therapeutic methods for treatment of cancer with a hif-2(alpha) inhibitor
CN112724167B (zh) * 2021-01-13 2022-11-11 湖北恒安芙林药业股份有限公司 一种克立硼罗的制备方法
US11827614B2 (en) 2021-05-21 2023-11-28 Merck Sharp & Dohme Llc Synthetic pathway to belzutifan and crystalline phases of synthetic intermediates
EP4347041A1 (en) 2021-05-28 2024-04-10 Taiho Pharmaceutical Co., Ltd. Small molecule inhibitors of kras mutated proteins
CN113651735B (zh) * 2021-08-27 2022-04-15 中国药科大学 一种HIF-2α抑制剂PT2385的制备方法
US12145901B1 (en) 2021-09-17 2024-11-19 Arcus Biosciences, Inc. Process for preparing tetralin compounds
EP4419089A4 (en) * 2021-10-18 2025-09-10 Nikang Therapeutics Inc HYPOXIA-INDUCIBLE FACTOR 2-(ALPHA) INHIBITORS FOR THE TREATMENT OF BLADDER CANCER
WO2023160552A1 (zh) * 2022-02-22 2023-08-31 南京明德新药研发有限公司 一类螺环类化合物及其应用
CN116178223B (zh) * 2022-04-15 2024-12-03 上海皓鸿生物医药科技有限公司 一种Belzutifan及其中间体的制备方法
CN114656379B (zh) * 2022-04-27 2024-06-04 成都道合尔医药技术有限公司 一种立他司特中间体的合成方法
CN115611847B (zh) * 2022-10-13 2024-04-30 南方科技大学坪山生物医药研究院 一种Belzutifan的中间体的制备方法
AR131039A1 (es) * 2022-11-14 2025-02-12 Hoffmann La Roche ARIL TIOÉTERES COMO INHIBIDORES DE HIF-2a
EP4688750A1 (en) 2023-04-06 2026-02-11 Pfizer Inc. Substituted indazole propionic acid derivative compounds and uses thereof as ampk activators
WO2025043187A1 (en) 2023-08-24 2025-02-27 Otsuka Pharmaceutical Co., Ltd. Fixed dose combinations of cedazuridine and azacitidine
AU2024361909A1 (en) 2023-10-20 2026-03-26 Merck Sharp & Dohme Llc Small molecule inhibitors of kras proteins
CN118005840B (zh) * 2024-04-08 2024-06-14 西南石油大学 一种热增稠自破胶压裂液稠化剂及其制备方法和应用
CN121449535B (zh) * 2025-12-31 2026-04-21 淄博飞源化工有限公司 光催化合成三氟甲磺酸的方法

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE705530C (de) * 1932-01-23 1941-04-30 Chem Fab Von Heyden Akt Ges Verfahren zur Darstellung von Polychlorsubstitutionsprodukten des Diphenylaethers
FR1574139A (https=) 1968-05-06 1969-07-11
US3905971A (en) * 1971-03-29 1975-09-16 Pfizer 2-Phenyl-as-triazine-3,5(2H,4H)diones
JPS4872169A (https=) 1971-12-28 1973-09-29
GB1448696A (en) * 1973-05-29 1976-09-08 Pfizer 2-phqnyl-astriazine-3,4-2h,4h-diones
GB2017087B (en) 1978-03-03 1982-09-02 Roussel Lab Ltd Process for the preparation of xanthone derivatives
US4214103A (en) * 1978-11-30 1980-07-22 Great Lakes Chemical Corporation Purification of brominated organic products
DE2938595A1 (de) * 1979-09-24 1981-04-23 Celamerck Gmbh & Co Kg, 6507 Ingelheim Verfahren zur herstellung von diphenylaethern
US4505929A (en) 1980-06-12 1985-03-19 The Dow Chemical Company Sulfur-substituted diphenyl ethers having antiviral activity
US4426385A (en) * 1980-10-16 1984-01-17 Union Carbide Corporation Insecticidal bicyclooxyphenyl ureas
DE3110894A1 (de) * 1981-03-20 1982-09-30 Celamerck Gmbh & Co Kg, 6507 Ingelheim Neue nitroaniline
DE3239449A1 (de) 1981-10-27 1983-05-05 CIBA-GEIGY AG, 4002 Basel Phenoxyphenyl- und pyridyloxyphenyl-derivate, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung
JPS58124758A (ja) * 1982-01-20 1983-07-25 Fujisawa Pharmaceut Co Ltd ベンゼンスルホンアミド誘導体
DE3209878A1 (de) 1982-03-18 1983-09-29 Celamerck Gmbh & Co Kg, 6507 Ingelheim Verfahren zur herstellung von diphenylaethern
US4665097A (en) 1983-03-31 1987-05-12 Union Carbide Corporation Novel bicyclooxyaryl thioureas and process for preparation
US4664097A (en) 1984-05-09 1987-05-12 The Wistar Institute Of Anatomy & Biology Nuclear transplantation in the mammalian embryo by microsurgery and cell fusion
US4705955A (en) * 1985-04-02 1987-11-10 Curt Mileikowsky Radiation therapy for cancer patients
JPS635136A (ja) 1986-06-26 1988-01-11 Mitsubishi Electric Corp 内燃機関のアイドル回転数制御装置
JPS6351363A (ja) 1986-08-21 1988-03-04 Tekukemu:Kk アミノ基を有するジフエニ−ル化合物の製造方法
US5059609A (en) 1987-10-19 1991-10-22 Pfizer Inc. Substituted tetralins, chromans and related compounds in the treatment of asthma, arthritis and related diseases
IL105777A0 (en) * 1992-06-04 1993-09-22 Great Lakes Chemical Corp Method for the isolation of a partially brominated diphenyl ether product
DE59408838D1 (de) 1993-08-27 1999-11-25 Hoffmann La Roche Tetrahydronaphthalin-Peptidderivate
DE4431219A1 (de) * 1994-09-02 1996-03-07 Bayer Ag Selektive Herbizide auf Basis von Aryluracilen
US6887820B1 (en) 1995-12-06 2005-05-03 Japan Science And Technology Corporation Method for producing optically active compounds
WO1997020789A1 (en) 1995-12-06 1997-06-12 Japan Science And Technology Corporation Process for preparating optically active compounds
AU6829298A (en) 1997-03-20 1998-10-20 Basf Aktiengesellschaft Substituted 2-benz(o)ylpyridines, their preparation and their use as herbicides
WO2001016097A1 (en) 1999-08-27 2001-03-08 Sugen, Inc. Phosphate mimics and methods of treatment using phosphatase inhibitors
DE60234100D1 (de) 2001-04-24 2009-12-03 Vlaams Interuniv Inst Biotech Verwendung von "hypoxia inducible factor 2alpha" zur behandlung von "neonatal respiratory distress syndrome"
EP1471049A4 (en) * 2002-01-30 2006-08-16 Kissei Pharmaceutical NEW THYROIDIAN HORMONE RECEPTOR LIGAND, MEDICINAL PREPARATIONS CONTAINING THE SAME AND USE THEREOF
US20050070474A1 (en) 2003-04-28 2005-03-31 Krissansen Geoffrey Wayne Methods of treatment and compositions therefor
SE0301906D0 (sv) * 2003-06-26 2003-06-26 Astrazeneca Ab New compounds
BRPI0418212A (pt) 2003-12-29 2007-04-27 Banyu Pharma Co Ltd composto ou um sal deste farmaceuticamente aceitável, ativador da glicocinase, e, medicamentos para a terapia e/ou prevenção da diabete, e da obesidade
US7612088B2 (en) 2004-05-28 2009-11-03 Speedel Experimenta Ag Heterocyclic compounds and their use as aldosterone synthase inhibitors
WO2006027684A1 (en) * 2004-09-10 2006-03-16 Pfizer Products Inc. Therapeutic diphenyl ether ligands
AU2005316739A1 (en) 2004-12-13 2006-06-22 Galileo Pharmaceuticals, Inc. Spiro derivatives as lipoxygenase inhibitors
EP1846379B1 (en) 2005-01-31 2009-08-19 Merck & Co., Inc. Antidiabetic bicyclic compounds
TW200714597A (en) 2005-05-27 2007-04-16 Astrazeneca Ab Chemical compounds
CN101291905A (zh) 2005-10-19 2008-10-22 弗·哈夫曼-拉罗切有限公司 苯乙酰胺nnrt抑制剂
CN101321529B (zh) * 2005-12-05 2012-09-05 大塚制药株式会社 作为抗肿瘤剂的二芳基醚衍生物
US7592461B2 (en) 2005-12-21 2009-09-22 Bristol-Myers Squibb Company Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
GB0526445D0 (en) * 2005-12-23 2006-02-08 Novartis Ag Organic compounds
LT1976828T (lt) 2005-12-29 2017-04-25 Celtaxsys, Inc. Diamino dariniai, kaip leukotrieno a4 hidrolazės inhibitoriai
WO2007099423A1 (en) 2006-03-02 2007-09-07 Pfizer Products Inc. 1-pyrrolidine indane derivatives as histamine-3 receptor antagonists
US20070244071A1 (en) 2006-03-07 2007-10-18 Mount Sinai Hospital Treatment of proliferative diseases
EP2021327B1 (en) * 2006-05-15 2012-04-04 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
CA2660957C (en) * 2006-08-23 2016-10-11 Neurogen Corporation 2-phenoxy pyrimidinone analogues
CA2682377A1 (en) 2007-03-30 2008-10-09 Nippon Shinyaku Co., Ltd. Heteroaryl derivatives
CN101058535B (zh) 2007-05-25 2010-07-21 复旦大学 二(7-羟基-2,3-二氢-1-1h-茚基)醚类及其类似物、合成方法及应用
HRP20100611T1 (hr) * 2007-06-06 2010-12-31 Torrent Pharmaceuticals Ltd Novi spojevi
WO2008157273A1 (en) 2007-06-14 2008-12-24 Smithkline Beecham Corporation Chemical compounds
CN101407467A (zh) * 2007-10-12 2009-04-15 中国人民解放军军事医学科学院毒物药物研究所 N-取代芳烃苯胺/多取代二芳基醚类化合物,其制备方法及抗肿瘤应用
CN101888999B (zh) * 2007-12-05 2013-12-11 巴斯夫欧洲公司 吡啶基甲基磺酰胺化合物
WO2009093133A1 (en) 2008-01-25 2009-07-30 Medichem, S.A. Method for determining the enantiomeric purity of indane derivatives
BRPI0909634A2 (pt) 2008-03-05 2015-09-22 Hoffmann La Roche 2-aminoquinolinas
US8188098B2 (en) 2008-05-19 2012-05-29 Hoffmann-La Roche Inc. GPR119 receptor agonists
AR074210A1 (es) * 2008-11-24 2010-12-29 Boehringer Ingelheim Int Derivados de pirimidina como inhibidores de ptk2-quinasa
US8691866B2 (en) 2008-12-10 2014-04-08 The General Hospital Corporation HIF inhibitors and use thereof
PE20120008A1 (es) * 2009-01-12 2012-01-24 Icagen Inc Derivados de fenoxi bencenosulfonamida
CA2754685A1 (en) 2009-03-11 2010-09-16 Pfizer Inc. Substituted indazole amides
WO2010137620A1 (ja) 2009-05-27 2010-12-02 武田薬品工業株式会社 フェノキシエチルアミン誘導体
WO2010141956A2 (en) 2009-06-05 2010-12-09 Caron Joan M Methods and compositions for the treatment of cancer
US8461164B2 (en) 2009-08-31 2013-06-11 Dow Agrosciences, Llc. Pteridines and their use as agrochemicals
JP2013509391A (ja) 2009-10-30 2013-03-14 グラクソ グループ リミテッド (3r,6r)−3−(2,3−ジヒドロ−1h−インデン−2−イル)−1−[(1r)−1−(2,6−ジメチル−3−ピリジニル)−2−(4−モルホリニル)−2−オキソエチル]−6−[(1s)−1−メチルプロピル]−2,5−ピペラジンジオンの新規結晶性形態
US8853277B2 (en) * 2009-11-30 2014-10-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nitroxide therapy for the treatment of von Hippel—Lindau disease (VHL) and renal clear cell carcinoma (RCC)
JP4902819B1 (ja) 2010-02-26 2012-03-21 株式会社日本触媒 フタロシアニン誘導体
GB201005589D0 (en) * 2010-04-01 2010-05-19 Respivert Ltd Novel compounds
US9024041B2 (en) 2010-04-08 2015-05-05 Respivert Ltd. P38 MAP kinase inhibitors
US9062072B2 (en) 2010-04-20 2015-06-23 Emory University Inhibitors of HIF and angiogenesis
US8853423B2 (en) 2010-06-17 2014-10-07 Seragon Pharmaceuticals, Inc. Indane estrogen receptor modulators and uses thereof
RS55186B1 (sr) 2010-07-29 2017-01-31 Astellas Pharma Inc Kondenzovana jedinjenja piridina kao ligandi cb2 kanabinoidnog receptora
EP2502917A1 (en) 2011-03-17 2012-09-26 Santhera Pharmaceuticals (Schweiz) AG Solid state crystalline forms of 4-(2-ethyl-5-fluoro-2,3-dihydro-1H-inden-2-yl)-1H-imidazole
WO2012170439A1 (en) 2011-06-06 2012-12-13 The Ohio State University Methods for stabilizing hypoxia inducible factor-2 alpha as a method for treating cancer
UY34200A (es) 2011-07-21 2013-02-28 Bayer Ip Gmbh 3-(fluorovinil)pirazoles y su uso
CA2849168A1 (en) 2011-09-22 2013-03-28 Merck Sharp & Dohme Corp. Cycloalkylnitrile pyrazole carboxamides as janus kinase inhibitors
WO2013057101A1 (de) 2011-10-17 2013-04-25 Bayer Intellectual Property Gmbh Substituierte oxadiazolylpyridinone und - pyridazinone als hif - hemmer
JP6014155B2 (ja) * 2011-10-31 2016-10-25 ゼノン・ファーマシューティカルズ・インコーポレイテッドXenon Pharmaceuticals Inc. ビアリールエーテルスルホンアミドおよび治療剤としてのそれらの使用
JP2015505542A (ja) 2012-01-28 2015-02-23 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung アザ複素環式化合物
JP6198715B2 (ja) 2012-03-06 2017-09-20 武田薬品工業株式会社 三環性化合物
MX355261B (es) 2012-06-21 2018-04-12 Eisai R&D Man Co Ltd Derivado de indanosulfamida novedoso.
WO2014031928A2 (en) 2012-08-24 2014-02-27 Philip Jones Heterocyclic modulators of hif activity for treatment of disease
EP2888253A4 (en) 2012-08-24 2016-01-06 Univ Texas HETEROCYCLIC HIF ACTIVITY MODULATORS FOR THE TREATMENT OF DISEASES
US20140128365A1 (en) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Pyridone/hydroxypyridine 11-beta hydroxysteroid dehydrogenase type i inhibitors
CA2890897A1 (en) 2012-11-14 2014-05-22 The Board Of Regents Of The University Of Texas System Inhibition of hif-2.alpha. heterodimerization with hif 1.beta. (arnt)
EP2925748B1 (en) * 2012-11-28 2017-01-11 Boehringer Ingelheim International GmbH Indanyloxydihydrobenzofuranylacetic acids as modulators of the g-protein coupled receptor 40 (gpr40) and of the free fatty acid receptor 1 (ffar1) for the treatment of metabolic diseases
US20140163025A1 (en) * 2012-12-07 2014-06-12 Boehringer Ingelheim International Gmbh Indanyloxydihydrobenzofuranylacetic acids
PL3417851T3 (pl) 2013-09-09 2020-12-14 Peloton Therapeutics, Inc. Etery arylowe i ich zastosowanie
US9884843B2 (en) 2013-12-16 2018-02-06 Peloton Therapeutics, Inc. Cyclic sulfone and sulfoximine analogs and uses thereof
WO2016145236A1 (en) 2015-03-11 2016-09-15 Peloton Therapeutics, Inc. Hif-2-alpha inhibitor polymorphs
WO2016144825A1 (en) 2015-03-11 2016-09-15 Peloton Therapeutics, Inc. Aromatic compounds and uses thereof
US10512626B2 (en) 2015-03-11 2019-12-24 Peloton Therapeautics, Inc. Compositions for use in treating glioblastoma
WO2016144826A1 (en) 2015-03-11 2016-09-15 Peloton Therapeutics, Inc. Substituted pyridines and uses thereof
US10278942B2 (en) 2015-03-11 2019-05-07 Peloton Therapeutics, Inc. Compositions for use in treating pulmonary arterial hypertension
WO2016168510A1 (en) 2015-04-17 2016-10-20 Peloton Therapeutics, Inc. Combination therapy of a hif-2-alpha inhibitor and an immunotherapeutic agent and uses thereof
US9796697B2 (en) 2015-06-12 2017-10-24 Peloton Therapeutics, Inc. Tricyclic inhibitors of HIF-2-alpha and uses thereof

Similar Documents

Publication Publication Date Title
JP2016534134A5 (https=)
JP2017511794A5 (https=)
JP2019518766A5 (https=)
JP2017509689A5 (https=)
JP2014508811A5 (https=)
JP2019501130A5 (https=)
RU2015107803A (ru) Производные дигидроксипиримидинкарбоновой кислоты и их применение в лечении, облегчении или предотвращении вирусного заболевания
JP2016540742A5 (https=)
JP2016513660A5 (https=)
RU2012116877A (ru) Соединения 2-пиридона, применяемые в качестве ингибиторов нейтрофильной эластазы
JP2016506369A5 (https=)
JP2020522520A5 (https=)
JP2017537940A5 (https=)
EA201391324A1 (ru) Бис(фторалкил)-1,4-бензодиазепиноновые соединения
HRP20201701T1 (hr) Aril eteri i njihove uporabe
JP2019517487A5 (https=)
JP2013518050A5 (https=)
JP2016500661A5 (https=)
JP2014051526A5 (https=)
JP2016503797A5 (https=)
JP2017501236A5 (https=)
HRP20170352T1 (hr) Spojevi bis(fluroalkil)-1,4-benzodiazepinona kao notch inhibitori
JP2010539110A5 (https=)
JP2013525458A5 (https=)
JP2015517574A5 (https=)